Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity
Peter Henriksen, Stephen Rankin, Ninian N. Lang
Abstract
A nthracyclines form the backbone of many chemotherapy protocols and are frequently used with curative intent in lymphoma, childhood leukemia, breast cancer, and other solid tumors.The potential for anthracycline-related myocardial injury and development of left ventricular (LV) dysfunction and heart failure (HF) remains a concern.This short-form primer will focus on the evidence for cardioprotection strategies to mitigate anthracycline cardiotoxicity in high-risk patients.
Topics & Concepts
CardiotoxicityAnthracyclineMedicineCardioprotectionInternal medicineHeart failureCardiologyChemotherapyOncologyIntensive care medicineBreast cancerCancerIschemiaChemotherapy-induced cardiotoxicity and mitigationCancer-related cognitive impairment studiesCancer Treatment and Pharmacology